Skip to main content
Erschienen in: The European Journal of Health Economics 4/2013

01.08.2013 | Editorial

The present state of health economics: a critique and an agenda for the future

verfasst von: Peter Zweifel

Erschienen in: The European Journal of Health Economics | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Excerpt

A couple of days ago, I was asked to give an interview concerning the conference ECHE 2012, the motto of which was, “Progress in Health Economics”. One of the questions posed to me was, “What is your vision of Health Economics 10 years from now?” Here is what I had to say. …
Literatur
1.
Zurück zum Zitat Beck, K., Zweifel, P., Trottmann, M.: Risk adjustment in health insurance and its long-term effectiveness. J. Health Econ. 29(4), 489–498 (2010)PubMedCrossRef Beck, K., Zweifel, P., Trottmann, M.: Risk adjustment in health insurance and its long-term effectiveness. J. Health Econ. 29(4), 489–498 (2010)PubMedCrossRef
2.
Zurück zum Zitat Eugster, P., Sennhauser, M., Zweifel, P.: Capping risk adjustment? J. Health Econ. 29(4), 499–507 (2010)PubMedCrossRef Eugster, P., Sennhauser, M., Zweifel, P.: Capping risk adjustment? J. Health Econ. 29(4), 499–507 (2010)PubMedCrossRef
3.
Zurück zum Zitat Kifmann, M., Roeder, K.: Premium subsidies and social health insurance: substitutes or complements? J. Health Econ. 30(6), 1207–1218 (2012)CrossRef Kifmann, M., Roeder, K.: Premium subsidies and social health insurance: substitutes or complements? J. Health Econ. 30(6), 1207–1218 (2012)CrossRef
4.
Zurück zum Zitat Schoder, J., Sennhauser, M., Zweifel, P.: Fine-tuning of health insurance regulation—unhealthy consequences for an individual insurer. Int. J. Econ. Bus. 17(3), 313–327 (2010)CrossRef Schoder, J., Sennhauser, M., Zweifel, P.: Fine-tuning of health insurance regulation—unhealthy consequences for an individual insurer. Int. J. Econ. Bus. 17(3), 313–327 (2010)CrossRef
5.
Zurück zum Zitat Sennhauser, M., Zweifel, P.: Ist ein neues Arzneimittel sein Geld wert? Wessen Geld? Submitted for publication in the German special edition of Pharmaco Econ (2012). Also available from the authors as: a new pharmaceutical: is it worth the money? Whose money? Sennhauser, M., Zweifel, P.: Ist ein neues Arzneimittel sein Geld wert? Wessen Geld? Submitted for publication in the German special edition of Pharmaco Econ (2012). Also available from the authors as: a new pharmaceutical: is it worth the money? Whose money?
6.
Zurück zum Zitat Van de Ven, W., Ellis, R.: Risk adjustment in competitive health plan markets. In: Newhouse, J.P., Culyer, A.J. (eds.) Handbook of Health Economics, vol. 1A, pp. 755–845. North-Holland, Amsterdam (2000) Van de Ven, W., Ellis, R.: Risk adjustment in competitive health plan markets. In: Newhouse, J.P., Culyer, A.J. (eds.) Handbook of Health Economics, vol. 1A, pp. 755–845. North-Holland, Amsterdam (2000)
7.
Zurück zum Zitat Zweifel, P. (ed.): Health, regulation, and the medical profession. Developments in health economics and public policy. Kluwer/Springer, Boston (1998) Zweifel, P. (ed.): Health, regulation, and the medical profession. Developments in health economics and public policy. Kluwer/Springer, Boston (1998)
8.
Zurück zum Zitat Zweifel, P., Breuer, M.: The case for risk-based premiums in public health insurance. Health Econ. Policy Law 1(2), 171–188 (2006)PubMedCrossRef Zweifel, P., Breuer, M.: The case for risk-based premiums in public health insurance. Health Econ. Policy Law 1(2), 171–188 (2006)PubMedCrossRef
Metadaten
Titel
The present state of health economics: a critique and an agenda for the future
verfasst von
Peter Zweifel
Publikationsdatum
01.08.2013
Verlag
Springer-Verlag
Erschienen in
The European Journal of Health Economics / Ausgabe 4/2013
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-012-0427-2

Weitere Artikel der Ausgabe 4/2013

The European Journal of Health Economics 4/2013 Zur Ausgabe